Supportive Care in Cancer · 2019 · 20 citations · 17 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyClinical PharmacologyAdjuvant ChemotherapyAdverse Effects Of ChemotherapyColorectal CancerCytotoxic ChemotherapyGastrointestinal Toxicity ManagementToxicity ManagementCapecitabine-based TherapyChemotherapy Medication SafetyChemotherapy-induced Gastrointestinal ToxicityDrug-induced Hand-foot SyndromeHand-foot Syndrome ManagementIncidence RatePhase Ii InvestigationSerious Adverse Events
PURPOSE: Capecitabine-based adjuvant chemotherapy for colorectal cancer patients often causes adverse events (AEs), such as diarrhea, stomatitis, anorexia, and hand-foot syndrome (HFS). Cystine and theanine were reported to attenuate some chemotherapy-associated AEs, and hence are also expected to attenuate capecitabine-induced AEs. Therefore, we aimed to investigate the safety and efficacy of cystine/theanine treatment in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery. METHODS: A total of 100 colorectal cancer patients treated with capecitabine as an adjuvant chemotherapy after surgery were randomly allocated into the cystine/theanine group (n = 52) or the placebo group (n = 48). The primary endpoint was incidence rate of diarrhea of grade 1 or higher in accordance with the Common Terminology Criteria for AEs (CTCAE) v.4.0, Japanese Clinical Oncology Group (JCOG) version. The secondary endpoints included incidence rates of other AEs (CTCAE v.4.0-JCOG), as well as the incidence rate of HFS according to the HFS grading scale. RESULTS: There were no significant differences in capecitabine-induced AEs between the two groups. However, the incidence rate of diarrhea of grade 1 or higher tended to be lower in the cystine/theanine group than the placebo group (18.4% vs. 28.9%, p = 0.169) as well as the incidence rate of HFS of grade 1 or higher (CTCAE v.4.0-JCOG or HFS grading scale) (67.4% vs. 77.8%, p = 0.185, 67.3% vs. 80.0%, p = 0.124, respectively). CONCLUSION: This trial demonstrated that cystine/theanine treatment of colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery is safe and has the tendency to reduce the incidence rate of diarrhea or HFS. TRIAL REGISTRATION: UMIN000024784.
17
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
A.-W. Chan, Jennifer Tetzlaff, Peter C Gøtzsche et al. · BMJ · 2013 · 7.1K citations · Full text
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Chris Twelves, A. Wong, Marek P. Nowacki et al. · New England Journal of Medicine · 2005 · 1.2K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Stefano Cascinu, Vincenzo Catalano, L. Cordella et al. · Journal of Clinical Oncology · 2002 · 416 citations
Medicine, Oncology, Pharmacology +17
Barry C. Lembersky, H. Samuel Wieand, Nicholas J. Petrelli et al. · Journal of Clinical Oncology · 2006 · 326 citations · Full text